organization · Reporting owner
Velan Capital, L.P.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PROGENICS PHARMACEUTICALS INCPGNX · Entity 148291 | 10% owner · See Explanation of Responses | September 09, 2019 | September 11, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PROGENICS PHARMACEUTICALS INC
Report date September 09, 2019 · Filed September 11, 2019
Jointly reported with Altiva Management Inc., VENKATARAMAN BALAJI
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.0013 par valueSEC Table I · non-derivative | Direct | 8,011,733 |
Reported balance
After 2019-09-09 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2019-09-09 · Purchase · Acquired 72,023 · Balance 8,011,733 F1: This Form 4 is filed jointly by Velan Capital, L.P. ("Velan Capital"), Altiva Management Inc. ("Altiva"), and Balaji Venkataraman (collectively, the "Reporting Persons"). The Reporting Persons may be deemed to be members of a Section 13(d) group that collectively beneficially owns more than 10% of the Issuer's outstanding shares of Common Stock. The Reporting Persons disclaim beneficial ownership of the securities of the Issuer owned directly by other members of the Section 13(d) group and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 or for any other purpose. Further, the Reporting Persons expressly disclaim beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. F2: Securities owned directly by Velan Capital. Each of Altiva, as the general partner of Velan Capital, and Mr. Venkataraman, as the sole shareholder of Altiva, may be deemed to beneficially own the securities owned directly by Velan Capital. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 is filed jointly by Velan Capital, L.P. ("Velan Capital"), Altiva Management Inc. ("Altiva"), and Balaji Venkataraman (collectively, the "Reporting Persons"). The Reporting Persons may be deemed to be members of a Section 13(d) group that collectively beneficially owns more than 10% of the Issuer's outstanding shares of Common Stock. The Reporting Persons disclaim beneficial ownership of the securities of the Issuer owned directly by other members of the Section 13(d) group and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 or for any other purpose. Further, the Reporting Persons expressly disclaim beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.
F2: Securities owned directly by Velan Capital. Each of Altiva, as the general partner of Velan Capital, and Mr. Venkataraman, as the sole shareholder of Altiva, may be deemed to beneficially own the securities owned directly by Velan Capital.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 09, 2019 Filed Sep 11, 2019 13:32 UTC | PROGENICS PHARMACEUTICALS INC PGNX · Entity 148291 | PurchaseCommon Stock, $0.0013 par value | 72,023 | $4.99 | $359,733.28 |
DisclosureSEC source: 0000921895-19-002393 · form412274002_09112019.xml · nonDerivative · entry 1 Velan Capital, L.P. · CIK 0001785731 · 10% owner · See Explanation of Responses Altiva Management Inc. · CIK 0001772491 · 10% owner · See Explanation of Responses VENKATARAMAN BALAJI · CIK 0001114916 · 10% owner · See Explanation of Responses Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,011,733 F1 · security: This Form 4 is filed jointly by Velan Capital, L.P. ("Velan Capital"), Altiva Management Inc. ("Altiva"), and Balaji Venkataraman (collectively, the "Reporting Persons"). The Reporting Persons may be deemed to be members of a Section 13(d) group that collectively beneficially owns more than 10% of the Issuer's outstanding shares of Common Stock. The Reporting Persons disclaim beneficial ownership of the securities of the Issuer owned directly by other members of the Section 13(d) group and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 or for any other purpose. Further, the Reporting Persons expressly disclaim beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. F2 · ownership.direct: Securities owned directly by Velan Capital. Each of Altiva, as the general partner of Velan Capital, and Mr. Venkataraman, as the sole shareholder of Altiva, may be deemed to beneficially own the securities owned directly by Velan Capital. Read SEC document |
| September 04, 2019 Filed Sep 5, 2019 16:37 UTC | PROGENICS PHARMACEUTICALS INC PGNX · Entity 148291 | PurchaseCommon Stock, $0.0013 par value | 243,614 | $4.51 | $1,098,528.61 |
DisclosureSEC source: 0000921895-19-002367 · form412274002_09052019.xml · nonDerivative · entry 2 Velan Capital, L.P. · CIK 0001785731 · 10% owner · See Explanation of Responses Altiva Management Inc. · CIK 0001772491 · 10% owner · See Explanation of Responses VENKATARAMAN BALAJI · CIK 0001114916 · 10% owner · See Explanation of Responses Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,939,710 F1 · security: This Form 4 is filed jointly by Velan Capital, L.P. ("Velan Capital"), Altiva Management Inc. ("Altiva"), and Balaji Venkataraman (collectively, the "Reporting Persons"). The Reporting Persons may be deemed to be members of a Section 13(d) group that collectively beneficially owns more than 10% of the Issuer's outstanding shares of Common Stock. The Reporting Persons disclaim beneficial ownership of the securities of the Issuer owned directly by other members of the Section 1(d) group and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 or for any other purpose. Further, the Reporting Persons expressly disclaim beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. F2 · ownership.direct: Securities owned directly by Velan Capital. Each of Altiva, as the general partner of Velan Capital, and Mr. Venkataraman, as the sole shareholder of Altiva, may be deemed to beneficially own the securities owned directly by Velan Capital. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 16:37 UTC | PROGENICS PHARMACEUTICALS INC PGNX · Entity 148291 | PurchaseCommon Stock, $0.0013 par value | 277,424 | $4.39 | $1,218,917.83 |
DisclosureSEC source: 0000921895-19-002367 · form412274002_09052019.xml · nonDerivative · entry 1 Velan Capital, L.P. · CIK 0001785731 · 10% owner · See Explanation of Responses Altiva Management Inc. · CIK 0001772491 · 10% owner · See Explanation of Responses VENKATARAMAN BALAJI · CIK 0001114916 · 10% owner · See Explanation of Responses Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,696,096 F1 · security: This Form 4 is filed jointly by Velan Capital, L.P. ("Velan Capital"), Altiva Management Inc. ("Altiva"), and Balaji Venkataraman (collectively, the "Reporting Persons"). The Reporting Persons may be deemed to be members of a Section 13(d) group that collectively beneficially owns more than 10% of the Issuer's outstanding shares of Common Stock. The Reporting Persons disclaim beneficial ownership of the securities of the Issuer owned directly by other members of the Section 1(d) group and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 or for any other purpose. Further, the Reporting Persons expressly disclaim beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. F2 · ownership.direct: Securities owned directly by Velan Capital. Each of Altiva, as the general partner of Velan Capital, and Mr. Venkataraman, as the sole shareholder of Altiva, may be deemed to beneficially own the securities owned directly by Velan Capital. Read SEC document |
| August 26, 2019 Filed Aug 27, 2019 15:45 UTC | PROGENICS PHARMACEUTICALS INC PGNX · Entity 148291 | PurchaseCommon Stock, $0.0013 par value | 73,230 | $4.30 | $314,910.97 |
DisclosureSEC source: 0000921895-19-002346 · form412274vel_08272019.xml · nonDerivative · entry 2 Velan Capital, L.P. · CIK 0001785731 · 10% owner · See Explanation of Responses Altiva Management Inc. · CIK 0001772491 · 10% owner · See Explanation of Responses VENKATARAMAN BALAJI · CIK 0001114916 · 10% owner · See Explanation of Responses Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,418,672 F1 · security: This Form 4 is filed jointly by Velan Capital, L.P. ("Velan Capital"), Altiva Management Inc. ("Altiva"), and Balaji Venkataraman (collectively, the "Reporting Persons"). The Reporting Persons may be deemed to be members of a Section 13(d) group that collectively beneficially owns more than 10% of the Issuer's outstanding shares of Common Stock. The Reporting Persons disclaim beneficial ownership of the securities of the Issuer owned directly by other members of the Section 1(d) group and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 or for any other purpose. Further, the Reporting Persons expressly disclaim beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. F2 · ownership.direct: Securities owned directly by Velan Capital. Each of Altiva, as the general partner of Velan Capital, and Mr. Venkataraman, as the sole shareholder of Altiva, may be deemed to beneficially own the securities owned directly by Velan Capital. Read SEC document |
| August 23, 2019 Filed Aug 27, 2019 15:45 UTC | PROGENICS PHARMACEUTICALS INC PGNX · Entity 148291 | PurchaseCommon Stock, $0.0013 par value | 130,826 | $4.31 | $563,689.99 |
DisclosureSEC source: 0000921895-19-002346 · form412274vel_08272019.xml · nonDerivative · entry 1 Velan Capital, L.P. · CIK 0001785731 · 10% owner · See Explanation of Responses Altiva Management Inc. · CIK 0001772491 · 10% owner · See Explanation of Responses VENKATARAMAN BALAJI · CIK 0001114916 · 10% owner · See Explanation of Responses Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,345,442 F1 · security: This Form 4 is filed jointly by Velan Capital, L.P. ("Velan Capital"), Altiva Management Inc. ("Altiva"), and Balaji Venkataraman (collectively, the "Reporting Persons"). The Reporting Persons may be deemed to be members of a Section 13(d) group that collectively beneficially owns more than 10% of the Issuer's outstanding shares of Common Stock. The Reporting Persons disclaim beneficial ownership of the securities of the Issuer owned directly by other members of the Section 1(d) group and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 or for any other purpose. Further, the Reporting Persons expressly disclaim beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. F2 · ownership.direct: Securities owned directly by Velan Capital. Each of Altiva, as the general partner of Velan Capital, and Mr. Venkataraman, as the sole shareholder of Altiva, may be deemed to beneficially own the securities owned directly by Velan Capital. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.